Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Leonard JP, et al. Among authors: krieg am. Clin Cancer Res. 2007 Oct 15;13(20):6168-74. doi: 10.1158/1078-0432.CCR-07-0815. Clin Cancer Res. 2007. PMID: 17947483 Clinical Trial.
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Ribas A, et al. Among authors: krieg am. Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425. Cancer Discov. 2021. PMID: 34326162 Free PMC article. Clinical Trial.
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Manegold C, et al. Among authors: krieg am. J Clin Oncol. 2008 Aug 20;26(24):3979-86. doi: 10.1200/JCO.2007.12.5807. J Clin Oncol. 2008. PMID: 18711188 Clinical Trial.
Cancer and inflammation: promise for biologic therapy.
Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Demaria S, et al. J Immunother. 2010 May;33(4):335-51. doi: 10.1097/CJI.0b013e3181d32e74. J Immunother. 2010. PMID: 20386472 Free PMC article. Review.
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. Saha A, et al. Among authors: krieg am. Cancer Immunol Immunother. 2006 May;55(5):515-27. doi: 10.1007/s00262-005-0009-6. Epub 2005 Jul 26. Cancer Immunol Immunother. 2006. PMID: 16044253 Free PMC article.
266 results